SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (30900)4/12/2009 3:49:03 PM
From: rkrw  Respond to of 52153
 
Cougar just started a p3 in chemo naive. So two shots on goal.

cougarbiotechnology.com

<<It would be a tragedy if they don't hit their survival endpoint and the FDA gives them grief, because the drug is clearly better than existing agents.>>



To: Biomaven who wrote (30900)5/21/2009 7:54:47 PM
From: Biomaven1 Recommendation  Read Replies (2) | Respond to of 52153
 
>>I could see Abiraterone ending up as the biggest partnership deal in biotech over the next year

So much for that prediction. JNJ takes them out at a measly 16% premium. I'll vote my few shares against the deal...

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News